• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

    4/10/23 9:37:13 AM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 RUBIUS THERAPEUTICS INC COMMON STOCK Cusip #78116T103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #78116T103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 298,019 Item 6: 0 Item 7: 298,019 Item 8: 0 Item 9: 298,019 Item 11: 0.329% Item 12: HC Cusip #78116T103 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 298,019 Item 8: 0 Item 9: 298,019 Item 11: 0.329% Item 12: IN Item 1(a). Name of Issuer: RUBIUS THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 124 WASHINGTON STREET, SUITE 101, C/O VERDOLINO & LOWEY, P.C. FOXBORO, MA 02035 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 78116T103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 298,019 (b) Percent of Class: 0.329% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 298,019 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of RUBIUS THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of RUBIUS THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. April 6, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on April 6, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of RUBIUS THERAPEUTICS INC at March 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RUBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cellarity Announces Close of $121 Million Series C Financing

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit

      10/4/22 7:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RUBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rubius Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Rubius Therapeutics from Buy to Neutral

      9/13/22 10:44:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously

      2/25/22 10:14:06 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously

      11/9/21 3:52:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Rubius Therapeutics Inc.

      15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/10/23 4:17:29 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/6/23 5:11:23 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25 filed by Rubius Therapeutics Inc.

      25 - Rubius Therapeutics, Inc. (0001709401) (Filer)

      3/28/23 4:23:38 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Appelhans Dannielle sold $1,323 worth of shares (10,385 units at $0.13), closing all direct ownership in the company

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/27/23 6:08:34 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Cagnoni Pablo J sold $2,112 worth of shares (8,448 units at $0.25), decreasing direct ownership by 11% to 66,082 units to cover withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:41:05 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Appelhans Dannielle converted options into 7,500 shares and sold $970 worth of shares (3,878 units at $0.25), increasing direct ownership by 54% to 10,385 units to satisfy withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:40:03 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care